GlassScriptPhysician profile
Philip G Huff
NPI 1972592632
$6,915.25
in general payments reported to CMS, 2019-2025
36 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $980 · 2021: $1,207 · 2022: $835 · 2023: $684 · 2024: $1,009 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.60 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.46 | 2019-2025 | |
| Amgen INC. | $827.61 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $809.20 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $678.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $489.49 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $483.80 | 2019-2025 | |
| Allergan, INC. | $286.86 | 2019-2020 | |
| Glaxosmithkline, LLC. | $204.23 | 2019-2025 | Shingrix, Arexvy |
| Inari Medical, INC. | $189.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.12 | 2019-2024 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $156.34 | 2019-2023 | Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $131.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.58 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Arbor Pharmaceuticals, INC. | $94.85 | 2019-2020 | |
| Antares Pharma, INC. | $85.25 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $73.41 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $69.49 | 2022-2023 | Ajovy |
| Esperion Therapeutics, INC. | $58.52 | 2021-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $51.31 | 2021 | |
| Endo Pharmaceuticals INC. | $48.92 | 2019-2021 | |
| Hologic Sales and Service, LLC | $44.87 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.64 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $39.70 | 2020-2025 | |
| Azurity Pharmaceuticals, INC. | $33.65 | 2023 | Edarbi |
| Ironwood Pharmaceuticals, INC | $30.34 | 2019 | |
| Circassia INC. | $24.80 | 2019 | |
| Astellas Pharma US INC | $22.76 | 2024 | Veozah |
| Bausch Health US, LLC | $22.00 | 2022 | |
| Eisai INC. | $20.05 | 2025 | |
| Therapeuticsmd, INC. | $19.96 | 2019 | |
| Clarus Therapeutics INC. | $17.29 | 2021 | |
| Genentech USA, INC. | $16.16 | 2020 | |
| Mannkind Corporation | $16.06 | 2020 | |
| Shire North American Group INC | $15.94 | 2019 | |
| Medtronic, INC. | $14.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.